FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304166260> ?p ?o ?g. }

• W4304166260 endingPage "113839" @default.
• W4304166260 startingPage "113839" @default.
• W4304166260 abstract "Immune checkpoint inhibitor (ICI) associated diabetes is a harmful adverse event (AE) in patients with cancer following anti-programmed (cell) death protein-1 (PD-1) treatment. There are no available biomarkers able to predict this AE. The primary aim of this study was to investigate C-peptide levels as potential predictor for the occurrence of ICI-related diabetes. The secondary aim was to describe the presence of islet autoantibodies and course of pancreatic enzymes in patients with and without ICI-related diabetes.From a total of 1318 patients with cancer who started anti-PD-1 treatment 8 cases and 16 controls were studied in this nested case-control study. C-peptide levels, islet autoantibodies, and pancreatic enzymes were measured in prospectively collected blood serum.In cases versus controls, median C-peptide levels were comparable at baseline and before toxicity or at the corresponding time point in controls. No patient had C-peptide levels below reference range before toxicity onset. Two out of eight patients in the ICI-related diabetes group had positive islet autoantibodies, whereas one out of 16 patients in the control group had positive islet autoantibodies. Pancreatic enzymes were elevated before diabetes onset in one patient (13%) and in one control (6%) at the corresponding time point.In patients developing ICI-related diabetes, changes in C-peptide levels, islet autoantibody positivity, and pancreatic enzymes before ICI-related diabetes onset seem comparable to patients without ICI-related diabetes. (NTR: NL6828)." @default.
• W4304166260 created "2022-10-11" @default.
• W4304166260 creator A5005955733 @default.
• W4304166260 creator A5009376752 @default.
• W4304166260 creator A5009918050 @default.
• W4304166260 creator A5012937808 @default.
• W4304166260 creator A5024891382 @default.
• W4304166260 creator A5037762412 @default.
• W4304166260 creator A5040710891 @default.
• W4304166260 creator A5045236213 @default.
• W4304166260 creator A5046383385 @default.
• W4304166260 creator A5050202217 @default.
• W4304166260 creator A5059303124 @default.
• W4304166260 creator A5065885053 @default.
• W4304166260 creator A5073885025 @default.
• W4304166260 creator A5074174053 @default.
• W4304166260 creator A5074901526 @default.
• W4304166260 creator A5084259742 @default.
• W4304166260 date "2022-12-01" @default.
• W4304166260 modified "2023-10-18" @default.
• W4304166260 title "The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy" @default.
• W4304166260 cites W2039415143 @default.
• W4304166260 cites W2049583719 @default.
• W4304166260 cites W2059471307 @default.
• W4304166260 cites W2076668534 @default.
• W4304166260 cites W2118471749 @default.
• W4304166260 cites W2152897456 @default.
• W4304166260 cites W2156353875 @default.
• W4304166260 cites W2222086386 @default.
• W4304166260 cites W2588916311 @default.
• W4304166260 cites W2612702080 @default.
• W4304166260 cites W2669889121 @default.
• W4304166260 cites W2736166064 @default.
• W4304166260 cites W2752227448 @default.
• W4304166260 cites W2772728378 @default.
• W4304166260 cites W2808896902 @default.
• W4304166260 cites W2810537535 @default.
• W4304166260 cites W2900174742 @default.
• W4304166260 cites W2910626396 @default.
• W4304166260 cites W2942850106 @default.
• W4304166260 cites W2962807330 @default.
• W4304166260 cites W3090536260 @default.
• W4304166260 cites W3092474711 @default.
• W4304166260 cites W3119919857 @default.
• W4304166260 doi "https://doi.org/10.1016/j.biopha.2022.113839" @default.
• W4304166260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36228374" @default.
• W4304166260 hasPublicationYear "2022" @default.
• W4304166260 type Work @default.
• W4304166260 citedByCount "2" @default.
• W4304166260 countsByYear W43041662602023 @default.
• W4304166260 crossrefType "journal-article" @default.
• W4304166260 hasAuthorship W4304166260A5005955733 @default.
• W4304166260 hasAuthorship W4304166260A5009376752 @default.
• W4304166260 hasAuthorship W4304166260A5009918050 @default.
• W4304166260 hasAuthorship W4304166260A5012937808 @default.
• W4304166260 hasAuthorship W4304166260A5024891382 @default.
• W4304166260 hasAuthorship W4304166260A5037762412 @default.
• W4304166260 hasAuthorship W4304166260A5040710891 @default.
• W4304166260 hasAuthorship W4304166260A5045236213 @default.
• W4304166260 hasAuthorship W4304166260A5046383385 @default.
• W4304166260 hasAuthorship W4304166260A5050202217 @default.
• W4304166260 hasAuthorship W4304166260A5059303124 @default.
• W4304166260 hasAuthorship W4304166260A5065885053 @default.
• W4304166260 hasAuthorship W4304166260A5073885025 @default.
• W4304166260 hasAuthorship W4304166260A5074174053 @default.
• W4304166260 hasAuthorship W4304166260A5074901526 @default.
• W4304166260 hasAuthorship W4304166260A5084259742 @default.
• W4304166260 hasBestOaLocation W43041662601 @default.
• W4304166260 hasConcept C126322002 @default.
• W4304166260 hasConcept C134018914 @default.
• W4304166260 hasConcept C159654299 @default.
• W4304166260 hasConcept C163764329 @default.
• W4304166260 hasConcept C165220095 @default.
• W4304166260 hasConcept C197934379 @default.
• W4304166260 hasConcept C203014093 @default.
• W4304166260 hasConcept C2778875212 @default.
• W4304166260 hasConcept C2779306644 @default.
• W4304166260 hasConcept C2781232474 @default.
• W4304166260 hasConcept C29730261 @default.
• W4304166260 hasConcept C555293320 @default.
• W4304166260 hasConcept C71924100 @default.
• W4304166260 hasConcept C90924648 @default.
• W4304166260 hasConceptScore W4304166260C126322002 @default.
• W4304166260 hasConceptScore W4304166260C134018914 @default.
• W4304166260 hasConceptScore W4304166260C159654299 @default.
• W4304166260 hasConceptScore W4304166260C163764329 @default.
• W4304166260 hasConceptScore W4304166260C165220095 @default.
• W4304166260 hasConceptScore W4304166260C197934379 @default.
• W4304166260 hasConceptScore W4304166260C203014093 @default.
• W4304166260 hasConceptScore W4304166260C2778875212 @default.
• W4304166260 hasConceptScore W4304166260C2779306644 @default.
• W4304166260 hasConceptScore W4304166260C2781232474 @default.
• W4304166260 hasConceptScore W4304166260C29730261 @default.
• W4304166260 hasConceptScore W4304166260C555293320 @default.
• W4304166260 hasConceptScore W4304166260C71924100 @default.
• W4304166260 hasConceptScore W4304166260C90924648 @default.
• W4304166260 hasLocation W43041662601 @default.
• W4304166260 hasLocation W43041662602 @default.

• next